Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Noiiglutide in Healthy Adults
NCT03203811Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of noiiglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Adverse Events at 1 week, Maximum Plasma Concentration at 1 week and 1 more. Started Feb 2017; status: completed.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03203811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203811.